Description

Simple

Clinical

Overview

Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

Pharmacology

Indication

Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.

Pharmacodynamic

Galiximab is a monoclonal antibody that is being studied in the treatment of follicular non-Hodgkin lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Galiximab binds to the protein CD80, which is found on certain normal and cancerous white blood cell... Read more

Mechanism of action

Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

13 to 24 days

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Galiximab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Galiximab.
Abituzumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Galiximab.
Adecatumumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Adecatumumab.
Aducanumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Galiximab is combined with Afelimomab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galiximab.
Alirocumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Alirocumab.
Amatuximab
The risk or severity of adverse effects can be increased when Galiximab is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when Galiximab is combined with AMG 108.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Galiximab is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Anifrolumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Galiximab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Galiximab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galiximab.
Apolizumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Apolizumab.
Apomab
The risk or severity of adverse effects can be increased when Galiximab is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when Galiximab is combined with Ascrinvacumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Galiximab is combined with Asfotase alfa.
3 References
  1. 1 . Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.PubMed: 15994148
  2. 2 . Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A: A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007 Jul;18(7):1216-23. Epub 2007 Apr 29.PubMed: 17470451
  3. 3 . Link Link